Loss Contingency, Patents Allegedly Infringed And Subsequently Revoked, Number

No definition available.

Name:	pfe_LossContingencyPatentsAllegedlyInfringedAndSubsequentlyRevokedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Ruled Invalid

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsRuledInvalid
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Ruled Invalid And Subsequently Revoked, Number

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsRuledInvalidAndSubsequentlyRevokedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Loss Contingency, Patents Under Review

+ References

No definition available.

+ Details

Name:	pfe_LossContingencyPatentsUnderReview
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Site Contingency, Regulatory Proceedings, Disclosure Threshold

+ References

No definition available.

+ Details

Name:	pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold
Namespace Prefix:	pfe_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483049/450-30-50-1

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found to have infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsFoundInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity was found not to have infringed.

+ References

+ Details

Name:	us-gaap_LossContingencyPatentsFoundNotInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ModernaTXEuropeanPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_ArbutusAndGenevantUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCIrelandInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUnifiedPatentCourtPatentInfringementCaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments - Patent Litigation (Details) $ in Millions	1 Months Ended
	Jul. 31, 2025 patent	Mar. 30, 2025 patent	Aug. 31, 2024 patent	Jul. 31, 2024 patent	Apr. 30, 2024 patent	Mar. 31, 2024 patent	Nov. 30, 2023 patent	May 31, 2023 patent	Apr. 30, 2023 patent	Sep. 30, 2022 patent	Aug. 31, 2022 patent	Jul. 31, 2022 patent	Dec. 31, 2025 USD ($)
Gain Contingencies [Line Items]
Threshold for disclosure of proceedings under environmental laws \| $													$ 1
Loss contingency, patents allegedly infringed and subsequently revoked							1
Comirnaty [Member] \| ModernaTX U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed											3
Number of patents ruled invalid		2
Number of patents under review						2
Comirnaty [Member] \| ModernaTX European Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed										2	2
Loss contingency, patents ruled invalid and subsequently revoked				1
Comirnaty [Member] \| Arbutus and Genevant U.S. Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed									5
Comirnaty [Member] \| GlaxoSmithKline Biologics SA and GlaxoSmithKline LLC US Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed			3		5
Comirnaty [Member] \| GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Ireland Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed	3
Comirnaty [Member] \| GlaxoSmithKline Biologics SA And GlaxoSmithKline LLC Unified Patent Court Patent Infringement Case [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed	2
Comirnaty [Member] \| Pfizer, BioNTech and BioNTech Manufacturing GmbH Versus CureVac, Judgment of Non-Infringement [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed												3
Number of patents found infringed								3